AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1646724
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (3.0 g) with 5 mg glipizide
Trial: 1646724
Drug: Aluminium hydroxide
RxNorm normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium hydroxide (1.0 g) with 5 mg glipizide
Trial: 1646724
Drug: Control (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (150 ml water with 5 mg glipizide)
Trial: 31925414
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence reminder and symptom management intervention using the Symptom Management Toolkit during eight automated telephone weekly calls.
Trial: 24820145
Drug: Atorvastatin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, 20 mg/day for 3 months
Trial: 17499292
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel instillation before periprostatic neurovascular bundle block
Trial: 17499292
Drug: Periprostatic neurovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic neurovascular bundle block without lidocaine gel instillation
Trial: 15350440
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) at a dose of 1.44 g/d (0.450 g/m² bid for children)
Trial: 11205489
Drug: EGCG 200
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG 200 mg
Trial: 26471236
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E 200 mg
Trial: 11205489
Drug: EGCG 400
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG 400 mg
Trial: 15958649
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E 400 mg
Trial: 11205489
Drug: EGCG 600
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG 600 mg
Trial: 26471236
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E 600 mg
Trial: 11205489
Drug: EGCG 800
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG 800 mg
Trial: 15958649
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E 800 mg
Trial: 27983689
Drug: Abobotulinum toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abobotulinum toxin A (100 units into each of the five lumbar extensor spinae muscles, total dose 500 to 1000 units)
Trial: 15854167
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment (5 mg/kg for induction, plus two maintenance infusions 8 weeks apart)
Trial: 10235439
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (4g daily for 12 weeks)
Trial: 10235439
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (4g daily for 12 weeks)
Trial: 1858085
Drug: Inhaled 15-(s)-hydroxyeicosatetraenoic
RxNorm normalized name: Methylcellulose (15 MPA.S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 15-(s)-hydroxyeicosatetraenoic acid (15-HETE) 80 nmol
Trial: 30160043
Drug: 6 mg/d
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/d melatonin supplements
Trial: 20659225
Drug: High FODMAP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High FODMAP diet (50 g/day)
Trial: 17965289
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide synthase inhibitor nitro‐L‐arginine methyl ester (L‐NAME) at doses of 0.5, 1, 2, and 4 mg/kg intravenously over 60 min
Trial: 17965289
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide synthase inhibitor nitro‐L‐arginine methyl ester (L‐NAME)
Trial: 17965289
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 ml normal saline)
Trial: 14572573
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg infliximab maintenance therapy
Trial: 14572573
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg infliximab maintenance therapy
Trial: 14572573
Drug: Single 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 mg/kg infliximab infusion (control group)
Trial: 8958890
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (starting at 40 mg/day, reducing by 5 mg every other day)
Trial: 8958890
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (2 mg daily)
Trial: 1586049
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen at 3 L/min delivered by concentrator
Trial: 1586049
Drug: Room air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room air at 3 L/min delivered by defective concentrator
Trial: 1586049
Drug: N/A (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N/A (no gas therapy)
Trial: 3857938
Drug: Intravaginal pessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal pessary of 3 mg prostaglandin E2 (PGE2)
Trial: 30712148
Drug: E-cigarettes with
RxNorm normalized name: E-Z Scrub with Ultradex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-cigarettes with nicotine salt formulations
Trial: 30712148
Drug: myblu 40-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: myblu 40-mg nicotine salt formulation
Trial: 27430941
Drug: Listening to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listening to 432 Hz music during endodontic treatment
Trial: 27430941
Drug: No music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No music during endodontic treatment
Trial: 22919757
Drug: High-dose Ganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Ganciclovir (7.5 mg/kg in inducement phase, 10 mg/kg in maintaining phase)
Trial: 22919757
Drug: Low-dose Ganciclovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Ganciclovir (5 mg/kg in inducement and maintaining phases)
Trial: 22919757
Drug: Low-dose Ganciclovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Ganciclovir
Trial: 20436079
Drug: Uncoupling index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncoupling index for cartilage collagen metabolism calculated from PIIANP and CTX-II measurements
Trial: 18778469
Drug: Lumiracoxib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 400 mg od
Trial: 18778469
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg od
Trial: 16171525
Drug: Interferon (IFN)-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon (IFN)-alpha in combination with lamivudine (n = 35)
Trial: 16171525
Drug: Interferon (IFN)-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon (IFN)-alpha alone or in combination with lamivudine
Trial: 11841050
Drug: Silymarin MZ-80
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin MZ-80 (150 mg t.i.d. per day)
Trial: 229091
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 4 drug chemotherapy (lomustine, methotrexate, cyclophosphamide, vincristine) and radiotherapy (3000 rad to primary chest lesion).
Trial: 23279003
Drug: Ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45 mg (Initial Responders)
Trial: 23279003
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg (Initial Responders)
Trial: 23279003
Drug: Ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45 mg (Partial Responders)
Trial: 23279003
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg (Partial Responders)
Trial: 22298147
Drug: Health-nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health-nutrition education and IFA pediatric tablet intervention with parental involvement
Trial: 12650785
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. for 2 weeks
Trial: 12650785
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus ranitidine 300 mg HS for 4 weeks
Trial: 12650785
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg QAM and QHS for 2 weeks
Trial: 12650785
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg every 8 hours for 2 weeks
Trial: 11242715
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with Lansoprazole (30 mg once a day), Amoxycillin (500 mg three times a day), and Roxythromycin (150 mg twice a day)
Trial: 11242715
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with Lansoprazole (30 mg once a day) and Amoxycillin (500 mg three times a day)
Trial: 1387500
Drug: Captopril 1
RxNorm normalized name: captopril 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 1 x 25 mg
Trial: 1387500
Drug: Ramipril 1
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 1 x 2.5 mg
Trial: 24485487
Drug: 1μg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1μg of cosyntropin administered intravenously
Trial: 22894958
Drug: CYD-TDV (tetravalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYD-TDV (tetravalent dengue vaccine)
Trial: 22894958
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (placebo for first dose, licensed hepatitis-A for children, influenza vaccine for adolescents and adults)
Trial: 17662087
Drug: Dronedarone 400
RxNorm normalized name: dronedarone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone 400 mg twice daily for 7 days
Trial: 12038948
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of cevimeline 3 times daily
Trial: 8529717
Drug: Covert monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Covert monitoring of inhalation
Trial: 8529717
Drug: Theophylline treatment
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline treatment (open randomized trial)
Trial: 8529717
Drug: Physician prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician prescribed doses of theophylline
Trial: 19639058
Drug: rhPDGF-BB (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhPDGF-BB (0.3 mg/mL) with freeze-dried bone allograft (FDBA; group A)
Trial: 19639058
Drug: rhPDGF-BB (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhPDGF-BB (0.3 mg/mL) with anorganic bovine bone graft (ABBG; group B)
Trial: 19639058
Drug: rhPDGF-BB (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhPDGF-BB (0.3 mg/mL) with anorganic bovine bone graft/mineralized collagen bone substitute (ABBG/MCBS; group C)
Trial: 17371357
Drug: Lamotrigine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (50 mg)
Trial: 11576883
Drug: 4 microg
RxNorm normalized name: Paricalcitol 4 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 microg of paricalcitol intravenously with the hemodialysis session three times weekly for 12 weeks
Trial: 9305517
Drug: Biological markers
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological markers using neuroimaging or other measures
Trial: 7870844
Drug: MCPP (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCPP (0.5 mg/kg)
Trial: 2680231
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of [1-13C]leucine (0.05 g/kg)
Trial: 2680231
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of unlabelled leucine (4 g)
Trial: 21474474
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg before operation and 75 mg twice daily for 5 days)
Trial: 16272755
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (specific drugs not mentioned)
Trial: 10550466
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day alendronate
Trial: 10550466
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day alendronate
Trial: 2081141
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 40 mg
Trial: 2081141
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 20 mg and 40 mg
Trial: 2081141
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 10 mg, 20 mg, and 40 mg
Trial: 120549
Drug: Deanol (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deanol (900 mg/day for 21 days)
Trial: 11159568
Drug: Agnus castus
RxNorm normalized name: Vitex agnus-castus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agnus castus (dry extract tablets) one tablet daily for three consecutive cycles
Trial: 11159568
Drug: Agnus castus
RxNorm normalized name: Vitex agnus-castus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agnus castus (dry extract tablets)
Trial: 31209718
Drug: Clinical medication
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical medication review (CMR)
Trial: 22613545
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg/d and 300 mg/d
Trial: 20434961
Drug: 900 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg/d of DHA orally for 24 weeks
Trial: 10208225
Drug: Betaxolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol (20 mg daily)
Trial: 7842188
Drug: Ethacrynic acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic acid 25 mg
Trial: 7842188
Drug: Ethacrynic acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic acid 50 mg
Trial: 2220345
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg twice daily for 2 weeks
Trial: 2220345
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets 1 tablet twice daily for 2 weeks
Trial: 28432894
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) treatment for OCD, PD/A, SAD, and GAD
Trial: 22192583
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (50 g daily)
Trial: 14674905
Drug: Five times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five times weekly application of short-contact dithranol (SCD)
Trial: 14674905
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times weekly application of short-contact dithranol (SCD)
Trial: 10505482
Drug: Sulpiride (150‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (150‐300 mg)
Trial: 9069860
Drug: Acupressure (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure (treatment group, n = 30) with bilateral elastic bands exerting pressure on the wrist during the perioperative period.
Trial: 6187310
Drug: High-dose gestagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gestagen therapy
Trial: 6187310
Drug: Chemotherapy (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cyclophosphamide, 5-fluorouracil, methotrexate, vinblastine)
Trial: 28131423
Drug: Preoperative use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative use of angiotensin receptor blockers (ARBs)
Trial: 28131423
Drug: No renin-angiotensin-system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No renin-angiotensin-system inhibitors
Trial: 28131423
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (ACEis)
Trial: 12527544
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy for generalized anxiety disorder in primary care (CBT‐GAD/PC)
Trial: 10664917
Drug: Celecoxib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (600 mg bid)
Trial: 9769898
Drug: Fast release
RxNorm normalized name: Delsym Cough Maximum Strength Fast Release Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast release tablet (FR 100 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Trial: 9769898
Drug: Fast-slow release
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-slow release tablet (FSR 150 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Trial: 9769898
Drug: Intramuscular solution
RxNorm normalized name: Intramuscular Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular solution (i.m. 100 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Trial: 9769898
Drug: Fast release
RxNorm normalized name: Delsym Cough Maximum Strength Fast Release Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast release tablet (FR 100 mg) vs Fast-slow release tablet (FSR 150 mg)
Trial: 3294190
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (30-90 mg daily)
Trial: 3294190
Drug: Indoramin (75-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (75-225 mg daily)
Trial: 21929768
Drug: Vigorous Intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigorous Intensity High Dose Exercise Augmentation (DEI)
Trial: 21929768
Drug: Health Education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Education Intervention Augmentation (HEI)
Trial: 18356552
Drug: B‐vitamins (folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐vitamins (folic acid 2 mg, vitamin B6 25 mg, and vitamin B12 0.5 mg)
Trial: 17162709
Drug: Intranasal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal E2 (n = 16)
Trial: 1964962
Drug: Thiotepa and
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thiotepa and Etoposide (total dose: Thiotepa 600-900 mg/M2 over 3 days, Etoposide 1500 mg/M2 over 3 days)
Trial: 1964962
Drug: Thiotepa, Etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiotepa, Etoposide and BCNU (total dose: BCNU 600 mg/M2 over 4 days)
Trial: 504040
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 650 mg (Control)
Trial: 6393443
Drug: B-diet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-diet plus 3 X 20 g fresh onion per day
Trial: 6393443
Drug: B-diet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-diet plus 3 X 200 g green beans per day